Previsioni
Il prezzo obiettivo medio degli analisti è 118,39 € (+1,54%). La mediana è 123,03 € (+5,52%).
| Acquista |
2 |
| Mantieni |
12 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Apogee Therapeutics reaches record high at $134.89
Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Altro su de.investing.com
Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie
Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Altro su de.investing.com
Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout
Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Altro su finance.yahoo.com
Apogee Therapeutics reaches record high of $134.34
Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Altro su de.investing.com
Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie
Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Altro su de.investing.com
Dati finanziari
Nell'ultimo trimestre, Apogee Therapeutics ha registrato ricavi pari a 0 € e un utile netto di -75,23 Mln €
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -75,23 Mln | 34,15% |
| EBITDA | -73,42 Mln | 31,86% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 7,66 Mld € |
Numero di azioni | 62,2 Mln |
Massimo/minimo a 52 settimane | 123,11 € - 32,25 € |
| Dividendi | No |
Beta | 0,34 |
Rapporto P/E | -31,12 |
Rapporto PEG | 6,57 |
Rapporto P/B | 8,53 |
Rapporto P/S | 0,00 |
Profilo aziendale
Apogee Therapeutics, Inc., tramite la sua controllata, opera come societa di biotecnologie che sviluppa biologici per il trattamento della dermatite atopica (AD), della broncopneumopatia cronica ostruttiva (BPCO) e di indicazioni infiammatorie e immunologiche correlate. La societa sviluppa principalmente APG777, un anticorpo monoclonale (mAb) sottocutaneo (SQ) a emivita estesa per la AD; e APG808, un mAb SQ a emivita estesa per la BPCO. I suoi programmi in fase piu precoce includono APG990, un mAb SQ a emivita estesa per il trattamento della AD; e APG222, anticorpi SQ a emivita estesa per la AD. La societa e stata fondata nel 2022 ed ha sede a Waltham, Massachusetts.
| Nome | Apogee Therapeutics |
| CEO | Michael Thomas Henderson |
| Sede centrale | Waltham,
ma Stati Uniti |
| Sito web | |
| Industria | Prodotti alimentari |
| Quotazione in borsa | 14/07/2023 |
| Dipendenti | 261 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | APGE |